Our patients are the heart of our company, and they, along with their families, friends and caregivers, are just as much members of the Imvax team. Patient care is our priority, and it is our joint effort and mission to change the course of cancer treatment and transform cancer outcomes.

At Imvax, Inc., we’re focused on the development of patient-specific vaccines and immunomodulatory strategies (therapies that utilize the body’s immune system) for the treatment of malignant gliomas (a specific type of brain tumor) and other cancers with unmet medical needs. As a company, we are obligated to ensure the safe and proper use of our investigational therapies and to provide access at the appropriate time, in the right manner and under the guidance of regulatory authorities, specifically the US Food and Drug Administration (FDA).

We are working with the FDA to expeditiously advance our investigational therapy, IGV-001, into the next phase of clinical development in GBM. This includes finalizing clinical sites and preparing those sites to accommodate patients and confirming proper manufacturing of our investigational therapy. At this time, Imvax, Inc. has no actively recruiting clinical trials.

Our next planned clinical trial to evaluate the safety and effectiveness of IGV-001 in GBM will be done in partnership with multiple major academic institutions. In the near future, we will post details on this website regarding the status of our next clinical trial.

If you or your physician have general questions regarding Imvax, Inc. or our autologous tumor cell vaccine, or would like to connect with one of our patient advocates, please contact us at .